Diabetologia (2017) 60:1561–1565 DOI 10.1007/s00125-017-4343-y EDITORIAL 60 years of metformin use: a glance at the past and a look to the future Sally M. Marshall Published online: 3 August 2017 Springer-Verlag GmbH Germany 2017 Abbreviations diabetes want medication that is effective at reducing blood DPP Diabetes Prevention Program glucose levels, easy to take, preferably has once-daily dosing, DPPOS Diabetes Prevention Program Outcomes Study has no short- or long-term side effects, carries no risk of eGFR Estimated GFR hypoglycaemia, does not cause weight gain and is affordable GLP-1 Glucagon-like peptide-1 worldwide. In addition, the ideal drug would address the un- PCOS Polycystic ovary syndrome derlying pathophysiology of type 2 diabetes and have added SGLT2 Sodium–glucose cotransporter 2 value in terms of reducing non-glycaemic risk factors for, and UKPDS UK Prospective Diabetes Study the incidence of, micro- and macrovascular complications of diabetes. How does metformin match up to these demands? The medication is certainly an effective glucose-lowering agent, generally reducing HbA by approximately 1c This year marks the 60th anniversary of the first clinical use of 10–15 mmol/mol (1.0–1.5%) in type 2 diabetes . metformin for diabetes. From small beginnings (and despite a However, we are beginning to realise that not
Diabetologia – Springer Journals
Published: Aug 3, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera